Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020:180:173-195.
doi: 10.1007/978-3-030-38862-1_6.

The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier

Affiliations

The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier

Sara I Pai et al. Cancer Treat Res. 2020.

Abstract

Checkpoint inhibitor therapy (CIT) has revolutionized cancer treatment but it has also reached a standstill when an absent dialog between cancer and immune cells makes it irrelevant. This occurs with high prevalence in the context of "immune silent" and, even perhaps, "immune-excluded" tumors. The latter are characterized by T cells restricted to the periphery of cancer nests. Since in either case T cells do not come in direct contact with most cancer cells, CIT rests immaterial. Adoptive cell therapy (ACT), may also be affected by limited access to antigen-bearing cancer cells. While lack of immunogenicity intuitively explains the immune silent phenotype, immune exclusion is perplexing. The presence of T cells at the periphery suggests that chemo-attraction recruits them and an immunogenic stimulus promotes their persistence. However, what stops the T cells from infiltrating the tumors' nests and reaching the germinal center (GC)? Possibly, a concentric gradient of increased chemo-repulsion or decreased chemo-attraction demarcates an abrupt "do not trespass" warning. Various hypotheses suggest physical or functional barriers but no definitive consensus exists over the weight that each plays in human cancers. On one hand, it could be hypothesized that the intrinsic biology of cancer cells may degenerate from a "cancer stem cell" (CSC)-like phenotype in the GC toward a progressively more immunogenic phenotype prone to immunogenic cell death (ICD) at the periphery. On the other hand, the intrinsic biology of the cancer cells may not change but it is the disorderly architecture of the tumor microenvironment (TME) that alters in a centripetal direction cancer cell metabolism, both directly and indirectly, the function of surrounding stromal cells. In this chapter, we examine whether the paradoxical exclusion of T cells from tumors may serve as a model to understand the requirements for tumor immune infiltration and, correspondingly, we put forth strategies to restore the dialog between immune cells and cancer to enhance the effectiveness of immune oncology (IO) approaches.

Keywords: Cancer immunotherapy; Combination therapy; Immune exclusion; Tumor microenvironment.

PubMed Disclaimer

Figures

Fig. 6.1
Fig. 6.1. The Paradox of Immune Exclusion—
Example of distinct theories that may explain the confined presence of T cells at the periphery of immune excluded cancer nests. a. Single immunohistochemical staining of PD-1 receptor on T cells in HNSCCs. Although there is some T cell infiltration into the tumor nests, the majority of the activated T cells remain in the tumor stroma and in the periphery of the tumor nest depicting immune exclusion. b Single immunohistochemical staining of PD-L1 on the tumor and/or immune cells on the same HNSCCs cut in serial section. There is strong PD-L1 expression in the periphery of the tumor nests as well as on tumor infiltrating TAMs. c Single immunofluorescent staining of PD-1 receptor. This is a high magnification of the area circled in red in Panel A. d Single immunofluorescent staining of PD-L1. This is a high magnification of the area circled in Panel B. e Dual immunofluorescent staining of PD-1 and PD-L1 with areas of overlap depicted as orange. f Dual immunofluorescent staining of PD-1 and PD-L1 with blue DAPI staining of single cell nuclei

References

    1. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J et al. (2019) Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer 7(1):131. - PMC - PubMed
    1. Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330 - PubMed
    1. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al. (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930–2940 - PMC - PubMed
    1. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567 - PMC - PubMed
    1. Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80 - PubMed